CNRClinical Neuroscience Research3083-48992981-8133Bio-Byword Scientific Publishing Pty. Ltd.10.26689/cnr.v4i1.14296ArticleComparative Efficacy of Interventions for Postpartum Depression: A Frequentist Network Meta-analysishttps://artdesignp.com/journal/CNR/4/1/10.26689/cnr.v4i1.14296ZengZhiqiang,LiangXuemei2026412026-03-19Objective: To compare the efficacy of different interventions for postpartum depression and to identify the intervention with the highest probability of benefit. Methods: Randomized controlled trials were identified through searches of PubMed, Embase, and Web of Science up to May 2023. The change in depression scores from baseline to post-intervention was extracted and synthesized as standardized mean differences (SMDs) using a frequentist network meta-analysis. Treatments were ranked according to the surface under the cumulative ranking curve (SUCRA). Results: Eight randomized controlled trials involving 641 participants were included. According to the SUCRA rankings, cognitive behavioral therapy (CBT) had the highest probability of being the most effective intervention. CBT did not significantly differ from fluoxetine (SMD 0.19, 95% CI -1.14 to 1.51), saffron (SMD 0.30, 95% CI -0.93 to 1.53), or sertraline (SMD 0.61, 95% CI -0.13 to 1.36), but it was superior to brexanolone (SMD 1.60, 95% CI 0.50 to 2.70) and zuranolone (SMD 1.72, 95% CI 0.61 to 2.84). Brexanolone and zuranolone did not significantly differ from each other (SMD 0.12, 95% CI -0.30 to 0.54), although both were superior to placebo. Conclusion: With the exception of estradiol, all interventions showed greater efficacy than placebo in reducing depressive symptoms. The ranking results suggest that CBT, fluoxetine, saffron, and sertraline may be among the more effective options for postpartum depression; however, these findings should be interpreted cautiously because of the limited number of studies and the scarcity of direct head-to-head comparisons.

Howard LM, Molyneaux E, Dennis CL, et al., 2014, Non-psychotic Mental Disorders in the Perinatal Period. Lancet, 384(9956): 1775–1788.

Ko JY, Rockhill KM, Tong VT, et al., 2017, Trends in Postpartum Depressive Symptoms: 27 States, 2004, 2008, and 2012. Morbidity and Mortality Weekly Report, 66(6): 153–158.

Vliegen, N, Casalin, S, and Luyten, P, 2014, The Course of Postpartum Depression: A Review of Longitudinal Studies. Harvard Review of Psychiatry, 22(1): 1–22.

Netsi E, Pearson RM, Murray L, et al., 2018, Association of Persistent and Severe Postnatal Depression with Child Outcomes. JAMA Psychiatry, 75(3): 247–253.

Stewart DE, Vigod S, 2016, Postpartum Depression. The New England Journal of Medicine, 375(22): 2177–2186.

Stewart DE, Vigod SN, 2019, Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics. Annual Review of Medicine, 2019(70): 183–196.

Kanes S, Colquhoun H, Gunduz-Bruce H, et al., 2017, Brexanolone (SAGE-547 injection) in Post-partum Depression: A Randomised Controlled Trial. Lancet, 390(10093): 480–489.

Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al., 2021, Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA Psychiatry, 78(9): 951–959.

Schober P, Mascha EJ, Vetter TR, 2021, Statistics from A (Agreement) to Z (z Score): A Guide to Interpreting Common Measures of Association, Agreement, Diagnostic Accuracy, Effect Size, Heterogeneity, and Reliability in Medical Research. Anesthesia & Analgesia, 133(6): 1633–1641.

Molyneaux E, Howard LM, McGeown HR, et al., 2014, Antidepressant Treatment for Postnatal Depression. Cochrane Database of Systematic Reviews, 2014(9): Cd002018.

Higgins JPT, Altman DG, Gøtzsche PC, et al., 2011, The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials. BMJ, 2011(343): d5928.

Wisner KL, Sit DKY, Moses-Kolko EL, et al., 2015, Transdermal Estradiol Treatment for Postpartum Depression: A Pilot, Randomized Trial. Journal of Clinical Psychopharmacology, 35(4): 389–395.

Kashani L, Eslatmanesh S, Saedi N, et al., 2017, Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial. Pharmacopsychiatry, 50(2): 64–68.

Meltzer-Brody S, Colquhoun H, Riesenberg R, et al., 2018, Brexanolone Injection in Post-Partum Depression: Two Multicentre, Double-Blind, Randomised, Placebo-controlled, Phase 3 Trials. Lancet, 392(10152): 1058–1070.

Milgrom J, Gemmill AW, Ericksen J, et al., 2015, Treatment of Postnatal Depression with Cognitive Behavioural Therapy, Sertraline and Combination Therapy: A Randomised Controlled Trial. Australian and New Zealand Journal of Psychiatry, 49(3): 236–245.

Tabeshpour J, Sobhani F, Sadjadi SA, et al., 2017, A Double-blind, Randomized, Placebo-Controlled Trial of Saffron Stigma (Crocus sativus L.) in Mothers Suffering from Mild-to-moderate Postpartum Depression. Phytomedicine, 2017(36): 145–152.

Hantsoo L, Ward-O’Brien D, Czarkowski KA, et al., 2014, A Randomized, Placebo-controlled, Double-blind Trial of sertraline for Postpartum Depression. Psychopharmacology (Berl), 231(5): 939–948.

Huang L, Zhao Y, Qiang C, et al., 2018, Is Cognitive Behavioral Therapy a Better Choice for Women with Postnatal Depression? A Systematic Review and Meta-analysis. PLoS One, 13(10): e0205243.

Pettman D, O’Mahen H, Blomberg O, et al., 2023, Effectiveness of Cognitive Behavioural Therapy-based interventions for Maternal Perinatal Depression: A Systematic Review and Meta-analysis. BMC Psychiatry, 23(1): 208.

National Institute for Health and Care Excellence (NICE), 2018, National Institute for Health and Care Excellence: Guidelines, in Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance. National Institute for Health and Care Excellence (NICE), London.

Dennis CL, Dowswell T, 2013, Psychosocial and Psychological Interventions for Preventing Postpartum Depression. Cochrane Database of Systematic Reviews, 2013(2): Cd001134.